{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T07:38:01Z","timestamp":1771486681506,"version":"3.50.1"},"reference-count":39,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2004,12,7]],"date-time":"2004-12-07T00:00:00Z","timestamp":1102377600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"The Medical Research Fund of Tampere University Hospital"},{"name":"The Ester M\u00e4kel\u00e4 Fund"},{"name":"The Nona and Kullervo V\u00e4re Foundation"},{"DOI":"10.13039\/100010744","name":"The Pirkanmaa Cancer Association","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100010744","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100009050","name":"Tampereen Lastenklinikan Tuki ry","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009050","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2005,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>This study was designed to evaluate the renal consequences of the treatment of brain tumor patients diagnosed in childhood.<\/jats:p><\/jats:sec><jats:sec><jats:title>Procedure<\/jats:title><jats:p>One hundred four primary brain tumor patients diagnosed before 17 years of age from 1983 to 1997 had been treated in Tampere University Hospital, Finland. Of the 80 survivors 52 (65.0%) were examined at a median age of 14.4 years (range 3.8\u201328.7) and median 6.0 years (range 1.2\u201314.8) after the last treatment. The main outcome measures were blood pressure (BP), renal function, and calcium metabolism.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Eight patients (15.4%) were hypertensive. Elevated BP was observed especially after exposure both to cisplatin and cranial irradiation. Spinal radiation did not increase the risk of elevated BP. Other adverse effects were observed only in patients treated with cisplatin. Five out of 14 patients treated with cisplatin evinced renal glomerular dysfunction (GFR\u2009&lt;\u200987 mL\/min\/1.73 m<jats:sup>2<\/jats:sup>) immediately after treatment. They had a high cumulative dose of cisplatin (490\u2013880 mg\/m<jats:sup>2<\/jats:sup>). Recovery from renal glomerular dysfunction was observed in one patient. Nine of 14 patients were hypomagnesemic at the close of cisplatin treatment. Thereafter the magnesium level decreased in 10\/14 cases (<jats:italic>P<\/jats:italic>\u2009=\u20090.006). During the study 10\/14 were hypomagnesemic (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001); one evinced severe symptomatic hypomagnesemia. Low plasma phosphate (<jats:italic>P<\/jats:italic>\u2009=\u20090.016) and potassium levels (<jats:italic>P<\/jats:italic>\u2009=\u20090.026), tubular proteinuria (<jats:italic>P<\/jats:italic>\u2009=\u20090.055), metabolic alkalosis (<jats:italic>P<\/jats:italic>\u2009=\u20090.071), and hyperuricemia (<jats:italic>P<\/jats:italic>\u2009=\u20090.114) were also more common in patients on cisplatin treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Elevated BP is common among brain tumor patients treated in childhood. After cisplatin treatment renal glomerular dysfunction appears mostly to be permanent. Persistent and even progressive changes in renal tubular function are seen. \u00a9 2004 Wiley\u2010Liss, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pbc.20272","type":"journal-article","created":{"date-parts":[[2004,12,7]],"date-time":"2004-12-07T21:46:09Z","timestamp":1102455969000},"page":"363-369","source":"Crossref","is-referenced-by-count":24,"title":["Renal impairment and hypertension in brain tumor patients treated in childhood are mainly associated with cisplatin treatment"],"prefix":"10.1002","volume":"44","author":[{"given":"Sari","family":"Pietil\u00e4","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marja","family":"Ala\u2010Houhala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanna L.","family":"Lenko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aimo P.T.","family":"Harmoinen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00e4in\u00f6","family":"Turjanmaa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"M\u00e4kipernaa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,12,7]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"9","article-title":"Cancer statistics","volume":"36","author":"Silverberg E","year":"1986","journal-title":"Cancer"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19930515)71:10 <3229::AID-CNCR2820711713>3.0.CO;2-7"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.36.5.597"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199412013312207"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11940-996-0003-0"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.2165\/00148581-200002010-00005"},{"key":"e_1_2_6_8_2","first-page":"297","article-title":"Effects of chemotherapy on kidney","volume":"13","author":"Cobos E","year":"1993","journal-title":"Semin Nephrol"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s004670100610"},{"key":"e_1_2_6_10_2","first-page":"1523","article-title":"Nephrotoxicity of cis\u2010dichlorodiammineplatinum (II)","volume":"63","author":"Krakoff I","year":"1979","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000042803.28024.92"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(05)83372-4"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(85)80098-6"},{"key":"e_1_2_6_14_2","first-page":"151","article-title":"Cisplatin nephrotoxicity: Symptomatic hypomagnesemia and renal failure","volume":"7","author":"Comez Campdera FJ","year":"1986","journal-title":"Int J Pediatr Nephrol"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1998.276"},{"key":"e_1_2_6_16_2","first-page":"213","article-title":"Eight drugs in 1 day chemotherapy for brain tumors: A new approach and rationale for preradiation chemotherapy","volume":"11","author":"Bleyer A","year":"1983","journal-title":"Med Pediatr Oncol"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-911X(199707)29:1<28::AID-MPO5>3.0.CO;2-U"},{"key":"e_1_2_6_18_2","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1001\/archinte.1997.00440420033005","article-title":"The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI)","volume":"157","author":"Joint National Committee","year":"1997","journal-title":"Arch Intern Med"},{"key":"e_1_2_6_19_2","first-page":"151","article-title":"1999 World Health Organization\u2010International Society of Hypertension guidelines for the management of hypertension","volume":"17","author":"Guidelines Subcommittee","year":"1999","journal-title":"J Hypertens"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(05)80382-8"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(67)92781-X"},{"key":"e_1_2_6_22_2","first-page":"181","volume-title":"Modern trends in pediatrics","author":"Barrat TM","year":"1974"},{"key":"e_1_2_6_23_2","first-page":"975","article-title":"Bilirubin and metamizol do not interfere with the randox enzymatic creatinine test. An evaluation of a new enzymatic creatinine determination method","volume":"34","author":"Harmoinen APT","year":"1996","journal-title":"Eur J Clin Chem Clin Biochem"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s004670050647"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.81.8.3051"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(20000501)88:9<2116::AID-CNCR18>3.0.CO;2-U"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19810115)47:2<245::AID-CNCR2820470207>3.0.CO;2-Q"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(82)90748-3"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1019998702946"},{"key":"e_1_2_6_30_2","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1542\/peds.98.4.649","article-title":"A Working Group Report from the National High Blood Pressure Education Program","volume":"98","author":"Update on the 1987 Task Force Report on High Blood Pressure in Children and Adolescents","year":"1996","journal-title":"Pediatrics"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9150(95)05525-2"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19940215)73:4<1297::AID-CNCR2820730427>3.0.CO;2-#"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6690697"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197905243002106"},{"key":"e_1_2_6_35_2","first-page":"1760","article-title":"Progressive renal insufficiency after CCNU therapy","volume":"77","author":"Berglund J","year":"1980","journal-title":"L\u00e4kartidningen"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-90-6-929"},{"key":"e_1_2_6_37_2","first-page":"85","article-title":"Hypomagnesemia following treatment of childhood cancer with cisplatinum","volume":"24","author":"Sheldon W","year":"1987","journal-title":"Ann Clin Biochem"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1136\/adc.65.7.732"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.10335"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/0090-8258(88)90052-2"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.20272","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.20272","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T01:19:47Z","timestamp":1696900787000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.20272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,12,7]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005,4]]}},"alternative-id":["10.1002\/pbc.20272"],"URL":"https:\/\/doi.org\/10.1002\/pbc.20272","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,12,7]]}}}